EA202190369A1 - Способ лечения эпилепсии - Google Patents

Способ лечения эпилепсии

Info

Publication number
EA202190369A1
EA202190369A1 EA202190369A EA202190369A EA202190369A1 EA 202190369 A1 EA202190369 A1 EA 202190369A1 EA 202190369 A EA202190369 A EA 202190369A EA 202190369 A EA202190369 A EA 202190369A EA 202190369 A1 EA202190369 A1 EA 202190369A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fenfluramine
epileptic seizure
racemate
fact
treatment
Prior art date
Application number
EA202190369A
Other languages
English (en)
Inventor
Джеффри Пол Бечард
Робин Пол Шеррингтон
Жан-Жак Александр Кадьё
Париса Карими Тари
Original Assignee
Ксенон Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксенон Фармасьютикалз Инк. filed Critical Ксенон Фармасьютикалз Инк.
Publication of EA202190369A1 publication Critical patent/EA202190369A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В некоторых вариантах осуществления настоящее изобретение направлено на способы и применение для лечения млекопитающего, страдающего эпилептическим судорожным расстройством или подверженного риску развития эпилептического судорожного расстройства, включающие введение определенных описанных в настоящем документе изолированных энантиомеров фенфлурамина, которые неожиданно эффективны в качестве противоэпилептических препаратов (ПЭП), несмотря на то, что они обладают меньшей противосудорожной активностью, чем рацемат фенфлурамина, в силу того, что они менее кардиотоксичны, чем рацемат фенфлурамина. Предпочтительные варианты осуществления предполагают лечение синдрома Драве; другие предпочтительные варианты осуществления предполагают лечение других эпилептических судорожных расстройств.
EA202190369A 2018-07-27 2019-07-26 Способ лечения эпилепсии EA202190369A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27
PCT/US2019/043765 WO2020023923A1 (en) 2018-07-27 2019-07-26 Method for treating epilepsy

Publications (1)

Publication Number Publication Date
EA202190369A1 true EA202190369A1 (ru) 2021-06-10

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190369A EA202190369A1 (ru) 2018-07-27 2019-07-26 Способ лечения эпилепсии

Country Status (19)

Country Link
US (1) US20200030260A1 (ru)
EP (1) EP3829558A1 (ru)
JP (1) JP2021530541A (ru)
KR (1) KR20210061332A (ru)
CN (1) CN112930175A (ru)
AU (1) AU2019310600A1 (ru)
BR (1) BR112021001135A2 (ru)
CA (1) CA3106031A1 (ru)
CL (1) CL2021000196A1 (ru)
CO (1) CO2021002087A2 (ru)
CR (1) CR20210095A (ru)
EA (1) EA202190369A1 (ru)
IL (1) IL280128A (ru)
MA (1) MA53329A (ru)
MX (1) MX2021000987A (ru)
PE (1) PE20211065A1 (ru)
PH (1) PH12021550176A1 (ru)
SG (1) SG11202100682YA (ru)
WO (1) WO2020023923A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
KR20180091924A (ko) 2015-12-22 2018-08-16 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
CN109689103A (zh) 2016-08-24 2019-04-26 周格尼克斯国际有限公司 用于抑制5-ht2b激动剂的形成的制剂及其使用方法
JP7383012B2 (ja) * 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
EP3999570A1 (en) * 2019-07-18 2022-05-25 Basf Se Allophanate based dispersing agent
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023034115A1 (en) * 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (ru) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
BR112017018297B1 (pt) * 2015-02-25 2023-12-05 The Regents Of The University Of California Uso de um agonista de receptor 5ht selecionado a partir de trazodona e lorcarserina, ou um sal farmaceuticamente aceitável dos mesmos, e uso de um agonista de receptor 5ht selecionado a partir de clemizol, um análogo de clemizol ou um sal farmaceuticamente aceitável dos mesmos
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
CR20210095A (es) 2021-06-01
US20200030260A1 (en) 2020-01-30
CN112930175A (zh) 2021-06-08
WO2020023923A1 (en) 2020-01-30
CL2021000196A1 (es) 2021-12-31
CA3106031A1 (en) 2020-01-30
AU2019310600A1 (en) 2021-02-11
SG11202100682YA (en) 2021-02-25
MA53329A (fr) 2022-03-02
JP2021530541A (ja) 2021-11-11
MX2021000987A (es) 2021-06-15
IL280128A (en) 2021-03-01
CO2021002087A2 (es) 2021-04-30
BR112021001135A2 (pt) 2021-04-20
KR20210061332A (ko) 2021-05-27
PE20211065A1 (es) 2021-06-09
EP3829558A1 (en) 2021-06-09
PH12021550176A1 (en) 2021-10-11

Similar Documents

Publication Publication Date Title
EA202190369A1 (ru) Способ лечения эпилепсии
Galanopoulou et al. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target
Duveau et al. Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy
Peterson et al. Astrocyte glutamate uptake and signaling as novel targets for antiepileptogenic therapy
Brandt et al. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats
Kishore et al. Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network
BR9602485A (pt) Método para o tratamento da doença de Parkinson composição farmacêutica primeira composição farmacêutica e método para a obtenção de efeito antiParkinson
Spiegel et al. A presumed case of phantom limb pain treated successfully with duloxetine and pregabalin
Singh et al. Agmatine for combined treatment of epilepsy, depression and cognitive impairment in chronic epileptic animals
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
RU2018115781A (ru) Условно активные полипептиды
Pazhoohan et al. Valproic Acid attenuates disease symptoms and increases endogenous myelin repair by recruiting neural stem cells and oligodendrocyte progenitors in experimental autoimmune encephalomyelitis
MX2022004342A (es) Degradadores bifuncionales dirigidos.
EA202092720A1 (ru) Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналов
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
Kan et al. Anticonvulsant effect of dexmedetomidine in a rat model of self-sustaining status epilepticus with prolonged amygdala stimulation
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
MX2022011518A (es) Metodos para tratar deambulacion asociada a proteinopatia.
MX2022013595A (es) Metodos de uso de moduladores del canal de calcio tipo t.
WO2013039956A3 (en) Compositions and methods for treating mood disorders
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ